The Cancer Immunotherapy Laboratory, The Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Neurosurgery Department, The Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Neuro Oncol. 2024 Mar 4;26(3):473-487. doi: 10.1093/neuonc/noad204.
GBM is an aggressive grade 4 primary brain tumor (BT), with a 5%-13% 5-year survival. Most human GBMs manifest as immunologically "cold" tumors or "immune deserts," yet the promoting or suppressive roles of specific lymphocytes within the GBM tumor microenvironment (TME) is of considerable debate.
We used meticulous multiparametric flow cytometry (FC) to determine the lymphocytic frequencies in 102 GBMs, lower-grade gliomas, brain metastases, and nontumorous brain specimen. FC-attained frequencies were compared with frequencies estimated by "digital cytometry." The FC-derived data were combined with the patients' demographic, clinical, molecular, histopathological, radiological, and survival data.
Comparison of FC-derived data to CIBERSORT-estimated data revealed the poor capacity of digital cytometry to estimate cell frequencies below 0.2%, the frequency range of most immune cells in BTs. Isocitrate dehydrogenase (IDH) mutation status was found to affect TME composition more than the gliomas' pathological grade. Combining FC and survival data disclosed that unlike other cancer types, the frequency of helper T cells (Th) and cytotoxic T lymphocytes (CTL) correlated negatively with glioma survival. In contrast, the frequencies of γδ-T cells and CD56bright natural killer cells correlated positively with survival. A composite parameter combining the frequencies of these 4 tumoral lymphocytes separated the survival curves of GBM patients with a median difference of 10 months (FC-derived data; P < .0001, discovery cohort), or 4.1 months (CIBERSORT-estimated data; P = .01, validation cohort).
The frequencies of 4 TME lymphocytes strongly correlate with the survival of patients with GBM, a tumor considered an immune desert.
GBM 是一种侵袭性 4 级原发性脑肿瘤(BT),5 年生存率为 5%-13%。大多数人类 GBM 表现为免疫“冷”肿瘤或“免疫荒漠”,然而,GBM 肿瘤微环境(TME)中特定淋巴细胞的促进或抑制作用仍存在较大争议。
我们使用细致的多参数流式细胞术(FC)来确定 102 例 GBM、低级别胶质瘤、脑转移瘤和非肿瘤性脑标本中的淋巴细胞频率。FC 获得的频率与“数字细胞计数”估计的频率进行比较。FC 获得的数据与患者的人口统计学、临床、分子、组织病理学、影像学和生存数据相结合。
FC 衍生数据与 CIBERSORT 估计数据的比较表明,数字细胞计数在估计 0.2%以下的细胞频率方面能力较差,而 BT 中大多数免疫细胞的频率就在该范围内。异柠檬酸脱氢酶(IDH)突变状态被发现比胶质瘤的病理分级更能影响 TME 组成。将 FC 与生存数据相结合表明,与其他癌症类型不同,辅助性 T 细胞(Th)和细胞毒性 T 淋巴细胞(CTL)的频率与胶质瘤的生存呈负相关。相比之下,γδ-T 细胞和 CD56bright 自然杀伤细胞的频率与生存呈正相关。结合这 4 种肿瘤淋巴细胞频率的综合参数将 GBM 患者的生存曲线分开,中位差异为 10 个月(FC 衍生数据;P<0.0001,发现队列),或 4.1 个月(CIBERSORT 估计数据;P=0.01,验证队列)。
4 种 TME 淋巴细胞的频率与被认为是免疫荒漠的 GBM 患者的生存强烈相关。